C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...
First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...
Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...
Lake Erie College of Osteopathic Medicine (LECOM) is reinforcing its commitment to accessible and affordable pharmacy ...
Therapeutic fasting offers a metabolic approach to chronic pain by shifting to fat metabolism, reducing systemic inflammation ...
April 14, 2026 - PRESSADVANTAGE - All Pro Gutter Guards has announced the expansion of its service line to include ...
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan ...
By combining online academics with clinical simulation, a nationwide initiative is removing bottlenecks in radiologic ...
Intelligent Investing explores how artificial intelligence enhances financial forecasting while human interpretation remains ...
Microbial infections, caused by bacteria, viruses, and parasites, pose a significant challenge to global health, affecting millions annually. Despite advancements in medical science, understanding the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results